Home    Back

Allo-apz2-eb    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
36Epidermolysis bullosa6

36. Epidermolysis bullosa    [ 147 clinical trials,   170 drugs,   (DrugBank: 40 drugs),   32 drug target genes,   113 drug target pathways]
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 147 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2018-001009-98-IT
(EUCTR)		11/10/201910/11/2020Study to investigate the efficacy and safety of allo-APZ2-EB on wound healing of epidermolysis bullosa (EB)An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB). - allo-APZ2-EB-II-01 Recessive dystrophic epidermolysis bullosa (RDEB)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Product Name: allo-APZ2-EB
Product Code: [allo-APZ2-EB]
Other descriptive name: Allogeneic skin-derived ABCB5-positive mesenchymal stem cells		RHEACELL GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes		18Phase 1United States;France;Austria;Germany;United Kingdom;Italy
2EUCTR2018-001009-98-DE
(EUCTR)		01/03/201903/05/2018Study to investigate the efficacy and safety of allo-APZ2-EB on wound healing of epidermolysis bullosa (EB)An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB) Recessive dystrophic epidermolysis bullosa (RDEB)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Product Name: allo-APZ2-EB
Product Code: allo-APZ2-EB
Other descriptive name: Allogeneic skin-derived ABCB5-positive mesenchymal stem cells		RHEACELL GmbH & Co. KGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		16Phase 1;Phase 2United States;France;Austria;Germany;United Kingdom;Italy
3NCT03529877
(ClinicalTrials.gov)		January 16, 201924/4/2018Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis BullosaAn Interventional, Multicenter, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-EB on Epidermolysis Bullosa (EB)Recessive Dystrophic Epidermolysis BullosaBiological: allo-APZ2-EBRHEACELL GmbH & Co. KGFGK Clinical Research GmbH;Granzer Regulatory Consulting & Services;Ticeba GmbHActive, not recruitingN/A55 YearsAll16Phase 1;Phase 2United States;Austria;France;Germany;United Kingdom;Italy
4EUCTR2018-001009-98-FR
(EUCTR)		07/01/201930/10/2018Study to investigate the efficacy and safety of allo-APZ2-EB on wound healing of epidermolysis bullosa (EB)An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB) Recessive dystrophic epidermolysis bullosa (RDEB)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		RHEACELL GmbH & Co. KGNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes		18Phase 1;Phase 2United States;France;Austria;Germany;United Kingdom
5EUCTR2018-001009-98-AT
(EUCTR)		05/11/201824/05/2018Study to investigate the efficacy and safety of allo-APZ2-EB on wound healing of epidermolysis bullosa (EB)An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB) Recessive dystrophic epidermolysis bullosa (RDEB)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Product Name: allo-APZ2-EB
Product Code: allo-APZ2-EB
Other descriptive name: Allogeneic skin-derived ABCB5-positive mesenchymal stem cells		RHEACELL GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes		16Phase 1;Phase 2United States;France;Austria;Germany;United Kingdom;Italy
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2018-001009-98-GB
(EUCTR)		18/09/201825/10/2018Study to investigate the efficacy and safety of allo-APZ2-EB on wound healing of epidermolysis bullosa (EB)An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB) Recessive dystrophic epidermolysis bullosa (RDEB)
MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]		Product Name: allo-APZ2-EB
Product Code: allo-APZ2-EB
Other descriptive name: Allogeneic skin-derived ABCB5-positive mesenchymal stem cells		RHEACELL GmbH & Co. KGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		16Phase 1;Phase 2United States;France;Austria;Germany;Italy;United Kingdom

Back to top